⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435731 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL336156 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL2671376 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL336112 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL8371729 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL1088139 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL28742939 | 0.97 | — | — | |
| SCHEMBL1067552 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL9188955 | 0.97 | CES2 (0.62) | — | |
| SCHEMBL1066379 | 0.97 | CES2 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1082 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180932-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | NESTLE SA (CH) | 2024-06-06 | — | — | US | claimed |
| EP-4313017-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | Société des Produits Nestlé S.A. (CH) | 2024-02-07 | — | — | EP | claimed |
| CN-117511774-A | Burkholderia as well as acquisition method and application thereof | 华南农业大学 | 2024-02-06 | — | — | CN | claimed |
| US-20240010589-A1 | SUBSTITUTED RESORCINOL COMPOUNDS AS AMPK ACTIVATORS, COMPOSITIONS, METHODS AND USES THEREOF | NESTLE SA (CH) | 2024-01-11 | — | — | US | claimed |
| US-20230414638-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | NESTLE SA (CH) | 2023-12-28 | — | — | US | claimed |
| WO-2023213715-A1 | AMPK ACTIVATOR (CBDA) AND SGLT2 INHIBITOR FOR METABOLIC HEALTH | Société des Produits Nestlé S.A. (CH) | 2023-11-09 | — | — | WO | claimed |
| CN-116981452-A | Substituted resorcinol compounds for the management of aging and related disorders | 雀巢产品有限公司 | 2023-10-31 | — | — | CN | claimed |
| EP-4247359-A1 | SUBSTITUTED RESORCINOL COMPOUNDS AS AMPK ACTIVATORS, COMPOSITIONS, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-09-27 | — | — | EP | claimed |
| CN-116761791-A | Substituted resorcinol compounds as AMPK activators and uses thereof | 雀巢产品有限公司 | 2023-09-15 | — | — | CN | claimed |
| EP-4240342-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2023-09-13 | — | — | EP | claimed |
| CN-106604714-B | The preparation method of α gels midbody composite and the O/W emulsification cosmetics containing α gels of use the composition | 株式会社资生堂 | 2018-10-12 | — | — | CN | claimed |
| CN-101287498-B | Psma antibody-drug conjugates | PSMA DEV COMPANY LLC | 2013-03-27 | — | — | CN | claimed |
| CN-101287498-A | PSMA antibody-drug conjugates | PSMA DEV COMPANY LLC (US) | 2008-10-15 | — | — | CN | claimed |
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | claimed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1355645-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON INC (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040097495-A1 | Method for treating fibrotic diseases or other indications IIIC | WAGLE DILIP (US) | 2004-05-20 | — | — | US | claimed |
| EP-1355645-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | Alteon, Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20020183365-A1 | Method for treating fibrotic diseases or other indications IIIC | ALTEON, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002067851-A2 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IIIC | ALTEON, INC. (US) | 2002-09-06 | — | — | WO | claimed |